Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

  • Technology appraisal guidance
  • TA257
  • Published: 

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the ACD

This page was last updated: 30 June 2011